Advanced Biomed Inc. Common Stock
ADVB · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.54 | 1.00 | 0.61 | -0.17 |
| FCF Yield | -1.20% | -3.01% | -4.37% | -3.97% |
| EV / EBITDA | 31,795.43 | -32.92 | -26.01 | -21.15 |
| Quality | ||||
| ROIC | -0.00% | -141.84% | -198.41% | -59.83% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.79 | 0.76 | 0.79 | 0.18 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | 91.71% | 30.72% | -54.66% | -311.20% |
| Safety | ||||
| Net Debt / EBITDA | 31,962.23 | 1.16 | 0.88 | 1.92 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | -1.98 | 0.00 | 0.00 |
| Cash Conversion Cycle | -738.04 | -18,229.64 | -19,429.62 | -62,140.66 |